Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).

被引：0
|
作者：
Kieran, Mark W.
Hargrave, Darren R.
Cohen, Kenneth J.
Aerts, Isabelle
Dunkel, Ira J.
Hummel, Trent Ryan
Jimenez, Irene
Pearson, Andrew D. J.
Pratilas, Christine A.
Whitlock, James
Bouffet, Eric
Shen, Wei-Ping Violet
Broniscer, Alberto
Bertozzi, Anne-Isabelle
Sandberg, Joan L.
Florance, Allison M.
Suttle, Benjamin B.
Haney, Pat
Russo, Mark W.
Geoerger, Birgit
机构：
[1] Dana Farber Canc Inst PND, Boston, MA 10021 USA
[2] Great Ormond St Hosp Children NHS Fdn Trust, London, 45229, England
[3] Johns Hopkins Univ SOM, Baltimore, MD USA
[4] Inst Curie, Paris, France
[5] Mem Sloan Kettering Canc Ctr, New York, NY M5G 1X8 USA
[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 92668 USA
[7] Royal Marsden Hosp, Surrey, 38105, England
[8] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[9] Hosp Sick Children, Toronto, ON, Canada
[10] Childrens Hosp Orange Cty, Orange, CA USA
[11] St Jude Childrens Res Hosp, Memphis, TN USA
[12] CHU Toulouse, Toulouse, France
[13] GlaxoSmithKline, Lansdale, PA USA
[14] GlaxoSmithKline, Durham, NC USA
[15] GlaxoSmithKline, RTP, Zebulon, NC USA
[16] GlaxoSmithKline, Philadelphia, PA USA
[17] GlaxoSmithKline, Bryn Mawr, PA USA
[18] Inst Gustave Roussy, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10004
引用
收藏
页数：1
相关论文
共 7 条
  • [1] The first study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas
    Kieran, M. W.
    Bouffet, E.
    Tabori, U.
    Broniscer, A.
    Cohen, K.
    Hansford, J.
    Geoerger, B.
    Hingorani, P.
    Dunkel, I.
    Russo, M.
    Tseng, L.
    Liu, Q.
    Nebot, N.
    Whitlock, J.
    Hargrave, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)
    Wen, Patrick
    Stein, Alexander
    van den Bent, Martin
    De Greve, Jacques
    Dietrich, Sascha
    De Vos, Filip
    von Bubnoff, Nikolas
    van Linde, Myra
    Lai, Albert
    Prager, Gerald
    Campone, Mario
    Fasolo, Angelica
    Lopez-Martin, Jose
    Kim, Tae Min
    Mason, Warren
    Hofheinz, Ralf-Dieter
    Blay, Jean-Yves
    Cho, Daniel
    Gazzah, Anas
    Gomez-Roca, Carlos
    Yachnin, Jeffrey
    Boran, Aislyn
    Burgess, Paul
    Palanichamy, Ilan
    Gasal, Eduard
    Subbiah, Vivek
    NEURO-ONCOLOGY, 2019, 21 : 19 - 19
  • [3] Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)
    Hargrave, D.
    Witt, O.
    Cohen, K.
    Packer, R.
    Lissat, A.
    Kordes, U.
    Laetsch, T. W.
    Hoffman, L.
    Lassaletta, A.
    Gerber, N. U.
    Gilheeney, S.
    Holm, S.
    Kramm, C.
    Sumerauer, D.
    Reitmann, C.
    Russo, M. W.
    Bouffet, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 132 - 132
  • [4] Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed refractory low-grade glioma.
    Kieran, Mark W.
    Bouffet, Eric
    Broniscer, Alberto
    Cohen, Kenneth J.
    Geoerger, Birgit
    Hansford, Jordan R.
    Hingorani, Pooja
    Aerts, Isabelle
    Andre, Nicolas
    Bertozzi-Salamon, Anne-Isabelle
    Dunkel, Ira J.
    Hummel, Trent Ryan
    Leary, Sarah
    Moreno, Lucas
    Russo, Mark W.
    Tseng, Lillian
    Dasgupta, Kohinoor
    Nebot, Noelia
    Whitlock, James
    Hargrave, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of BRAF V600E Mutation, BRAF Fusion, and Wild-Type Tumors in Patients without Neurofibromatosis-1
    Trasolini, A.
    Erker, C.
    Cheng, S.
    Crowell, C.
    McFadden, K.
    Moineddin, R.
    Sargent, M. A.
    Mata-Mbemba, D.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2022, 43 (08) : 1196 - 1201
  • [6] Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
    Hargrave, Darren R.
    Bouffet, Eric
    Tabori, Uri
    Broniscer, Alberto
    Cohen, Kenneth J.
    Hansford, Jordan R.
    Geoerger, Birgit
    Hingorani, Pooja
    Dunkel, Ira J.
    Russo, Mark W.
    Tseng, Lillian
    Dasgupta, Kohinoor
    Gasal, Eduard
    Whitlock, James A.
    Kieran, Mark W.
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7303 - 7311
  • [7] MR IMAGING OF PEDIATRIC LOW-GRADE GLIOMAS: PRETHERAPEUTIC DIFFERENTIATION OF BRAF V600E MUTATION, BRAF-FUSED AND WILD-TYPE TUMORS IN PATIENTS WITHOUT NEUROFIBROMATOSIS-1
    Trasolini, Andrew
    Erker, Craig
    Cheng, Sylvia
    Crowell, Cameron
    McFadden, Kathryn
    Moineddin, Rahim
    Sargent, Michael
    Mata-Mbemba, Daddy
    NEURO-ONCOLOGY, 2022, 24 : 88 - 89
1